Channel Therapeutics announces efficacy results for eye drop formulations

Written by Emily J. Thompson, Senior Investment Analyst

Updated: May 14 2025

0mins

Clinical Trials Success: Channel Therapeutics Corporation has successfully met its endpoints in two pre-clinical trials for eye drop formulations aimed at treating acute ocular pain and chronic dry eye disease, demonstrating significant efficacy in reducing pain in animal models.
NaV1.7 Target Validation: The results support the potential of NaV1.7 as a target for various pain treatments, reinforcing the company's belief in its broad applications for pain management, as highlighted by Dr. Eric Lang, the Chief Medical Officer.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.